Atopic Dermatitis Sleep Study (Topical cream)
We know these are challenging times and venturing out can be especially stressful. We want you to know that at CRCC we have implemented every safety measure possible to keep you safe and prevent the spread of Covid-19. Patient areas are continually disinfected, social distancing is enforced in our lobby, and all staff wear masks/gloves throughout the day. If you arrive for your appointment and wish to wear a mask, we will provide one for you as well.
About Atopic Dermatitis
Eczema/Atopic Dermatitis is a complex disease that is determined by genetic, environmental, and immunologic factors. It is one of the most common chronic medical diseases that is characterized by redness, itching, thickening of the skin and crusted areas. Flares are frequently triggered by exposure to environmental factors, irritants, and allergens. Patients may have a high disease burden and their life quality is significantly affected.
About the Study
We are seeking volunteers who meet the below criteria to participate in a clinical study to assess treatment with Ruxolitinib cream 1.5% and if it decreases sleep impairment related to atopic dermatitis itch. The study is 8 weeks in duration with a 1 month follow-up post treatment.
Am I Eligible?
- Must be 18 or older
- Chronic AD diagnosis for a minimum of 2 years, and shown documented history of itch for at least 3 months
- BSA of 3%-20%, 1% is approximately equal to the size of your palm
- Willing to wear an Ōura ring device to collect sleep data
- has access to broadband wireless internet and is willing to connect a wireless device to the wireless network (to be installed by a third party)
- Agree to spend 95% of nights in the household during the study (no travel)
- No health insurance required
- Compensation may be provided for time and travel
If you are interested in participating in one of these studies, please provide your contact information below. If you are a qualified candidate, a representative from our research department will be in touch with you.